GnRH antagonists have important differences in their PK profiles
The currently available GnRH antagonists have important differences in their PK profiles. This may have important implications in how they need to be taken –… Read More
The currently available GnRH antagonists have important differences in their PK profiles. This may have important implications in how they need to be taken –… Read More
While the primary efficacy of currently available GnRH antagonists is assessed in the same way (i.e. proportion of responders with ≤80ml uterine blood loss per… Read More
It is well documented that UF affects Black women more commonly – with 2-3-fold higher incidence vs White women.1 Not only is UF more common… Read More
Not all GnRH antagonists have been formulated in the same way and there are important differences in the level of efficacy and tolerability they can… Read More
There may be important differences in the effect different GnRH antagonists can have on bone – especially if there are different dose strengths available and… Read More
Full estradiol suppression with GnRH antagonists alone can result in hypoestrogenic side effects such as hot flushes and loss of BMD1,2 Combining add-back therapy (ABT)… Read More
Full estradiol suppression with GnRH antagonists alone can result in hypoestrogenic side effects, such as the loss of bone mineral density (BMD)1,2 A reduction in… Read More
Full estradiol suppression with GnRH antagonists alone can result in an increase in hypoestrogenic side effects such as vasomotor symptoms (VMS).1,2 The most common symptoms… Read More
There may be important differences between the available GnRH antagonists, in terms of which patients they can be used in and how and what level… Read More
The efficacy of all available GnRH antagonists has been tested through RCTs and approved by the necessary regulatory bodies (e.g., EMA, FDA). At 24 weeks,… Read More
